Please assess the completion status of the following clinical trial:

Trial Title: Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have presumed malignant glioma based on clinical and radiologic evaluation (pathologic confirmation of malignant glioma must be made at the time of stereotactic biopsy or resection prior to NSC-CRAd-S-pk7 injection; if this is not possible, the injection will not be performed and the subject will no longer be eligible for the study).~* Tumor must be accessible for injection and must not be located in the brainstem, or contained within the ventricular system.~* Planning to undergo standard radiation/chemotherapy~* 18 years of age or older.~* Performance status must be KPS ≥ 70~* SGOT (AST) \< 3x upper limit of normal~* Serum creatinine \< 2mg/dl~* Platelets \> 100,000/mm3 and WBC \> 3000/mm3~Exclusion Criteria:~* Prior or ongoing liver disease including known cirrhosis, hepatitis B or C infection but not to exclude patients with a distant history of resolved hepatitis A infection.~* Immunosuppressive drugs (with exception of corticosteroid).~* Known HIV+ patients.~* Acute infections (viral, bacterial or fungal infections requiring therapy).~* Pregnant or breast-feeding patients.~* Evidence of metastatic disease or other malignancy (except squamous or basal cell skin cancers).~* Prior radiation therapy to the brain or prior treatment for brain tumor Other serious co-morbid illness or compromised organ function.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Unresectable disease (Type: EXPERIMENTAL): Patients with unresectable tumors will undergo a biopsy followed by injection of neural stem cells loaded with the virus and then receive standard chemoradiotherapy.
- Resectable disease (Type: EXPERIMENTAL): Patients with resectable tumors will undergo a resection followed by injection of neural stem cells loaded with the virus and then receive standard chemoradiotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).